Conjugates comprising an antibody specific for the ED-B domain of fibronectin and their use for the detection and treatment of tumours

Details for Australian Patent Application No. 2003210149 (hide)

International Classifications

Event Publications

17 July 2003 Complete Application Filed

Priority application(s): 60/358,702 25.02.02 US; 02000315.8 03.01.02 EP

4 September 2003 Application Open to Public Inspection

Published as AU-B-2003210149

18 September 2008 Alteration of Name

The name of the applicant has been altered to Bayer Schering Pharma Aktiengesellschaft

9 October 2008 Application Accepted

Published as AU-B-2003210149

5 February 2009 Standard Patent Sealed

8 December 2011 Offer to Surrender

Bayer Schering Pharma Aktiengesellschaft Mullerstrasse 178 , 13153 Berlin , the Patentee of Letters Patent 2003210149 dated 22.01.2009 for an invention titled ' Conjugates comprising an antibody specific for the ED-B domain of fibronectin and their use for the detection and treatment of tumours' offers to surrender the said Letters Patent. Any person desiring to be heard before the said offer to surrender is accepted must lodge a request to be heard within one month from the date of this journal.

2 February 2012 Offer to Surrender

The offer by the Patentee Bayer Schering Pharma Aktiengesellschaft to surrender Letters Patent 2003210149 which was advertised in the Official Journal of 08.12.2011 has been accepted and the Letters Patent has been revoked in accordance with Section 137 of the Patents Act.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.